Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Merck
Cipla
US Army
Medtronic
Farmers Insurance
US Department of Justice
Cantor Fitzgerald

Generated: February 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TRIFLUOPERAZINE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Trifluoperazine Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT01765829 Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis Unknown status Instituto de Salud Carlos III Phase 3 The purpose of this study is to assess if patients who continue with antipsychotic treatment for 12 or more months show the same risk of relapse (measured by PANSS) that patients with the same medical condition who have followed a discontinuation treatment scheme based in the presence of prodromes. The candidates should accomplish the following criteria: first episode of non-affective psychosis who have followed antipsychotic treatment for 12 months and who have already shown remission criteria.
NCT01765829 Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis Unknown status Fundación Pública Andaluza Progreso y Salud Phase 3 The purpose of this study is to assess if patients who continue with antipsychotic treatment for 12 or more months show the same risk of relapse (measured by PANSS) that patients with the same medical condition who have followed a discontinuation treatment scheme based in the presence of prodromes. The candidates should accomplish the following criteria: first episode of non-affective psychosis who have followed antipsychotic treatment for 12 months and who have already shown remission criteria.
NCT02582736 Antipsychotics and Risk of Hyperglycemic Emergencies Completed Canadian Institutes of Health Research (CIHR) N/A The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.
NCT02582736 Antipsychotics and Risk of Hyperglycemic Emergencies Completed Drug Safety and Effectiveness Network, Canada N/A The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.
NCT02582736 Antipsychotics and Risk of Hyperglycemic Emergencies Completed Canadian Network for Observational Drug Effect Studies, CNODES N/A The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.
NCT02600741 Family Intervention in Recent Onset Schizophrenia Treatment (FIRST) Recruiting Janssen Scientific Affairs, LLC Phase 4 The primary purpose of this study is to evaluate the overall effect of caregivers receiving a study-provided caregiver psycho-education and skills training program on the number of treatment failures (psychiatric hospitalization, psychiatric emergency room (ER) visit, crisis center visit, mobile crisis unit intervention, arrest/incarceration, and suicide or suicide attempt) in patients under their care during a 12 month period.
NCT02704962 Olanzapine vs. Low-dose Olanzapine Plus Trifluoperazine Completed Department of Health, Executive Yuan, R.O.C. (Taiwan) Phase 4 The investigators hypothesis is that an antipsychotic drug combination of low-dose olanzapine plus low-dose trifluoperazine is similar to regular-dose olanzapine monotherapy in efficacy and safety for treatment of schizophrenia.The goal of this study is to compare the efficacy and safety of the olanzapine (10 mg/d) and olanzapine (5 mg/d) plus trifluoperazine (5 mg/d) in the treatment of acute psychotic exacerbations of schizophrenia.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Trifluoperazine Hydrochloride

Condition Name

Condition Name for Trifluoperazine Hydrochloride
Intervention Trials
Schizophrenia 3
Bipolar Disorder 2
Schizoaffective Disorder 1
Psychotic Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Trifluoperazine Hydrochloride
Intervention Trials
Schizophrenia 3
Bipolar Disorder 2
Psychotic Disorders 2
Mental Disorders 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Trifluoperazine Hydrochloride

Trials by Country

Trials by Country for Trifluoperazine Hydrochloride
Location Trials
United States 23
Spain 9
Canada 1
China 1
Taiwan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Trifluoperazine Hydrochloride
Location Trials
Ohio 2
California 1
Oregon 1
Pennsylvania 1
Rhode Island 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Trifluoperazine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Trifluoperazine Hydrochloride
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Trifluoperazine Hydrochloride
Clinical Trial Phase Trials
Recruiting 3
Completed 2
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Trifluoperazine Hydrochloride

Sponsor Name

Sponsor Name for Trifluoperazine Hydrochloride
Sponsor Trials
Haining Health-Coming Biotech Co., Ltd. 1
Canadian Institutes of Health Research (CIHR) 1
Lindner Center of HOPE 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Trifluoperazine Hydrochloride
Sponsor Trials
Other 9
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Covington
Federal Trade Commission
Express Scripts
Fish and Richardson
AstraZeneca
Baxter
UBS
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.